Arrowhead Presents Positive Data on ARC-520 in Hepatitis B Infected Chimpanzees at AASLD Liver Meeting 2015 - Arrowhead Pharma (NASDAQ:ARWR)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Arrowhead Research Corporation (NASDAQ: ARWR) presents data at the AASLD Liver Meeting 2015 in an oral presentation and a poster showing that ARC-520, its drug candidate against chronic hepatitis B infection (HBV), leads to robust, sustained anti-viral effects in chimpanzees with chronic HBV. Arrowhead also describes an important new discovery that HBV DNA integrated into the host genome is likely an important source of HBV surface antigen (HBsAg) production, particularly in chimps that are negative for hepatitis B e-antigen (HBeAg). The company plans to present additional data from this study at the 2015 Hep Dart conference in December demonstrating that two of four HBeAg-positive chimps exhibited signs of immune reactivation, which is

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release